321 related articles for article (PubMed ID: 3247706)
1. [Treatment of Raynaud's syndrome in systemic connective tissue diseases with calcium antagonists].
Shcherbakov AB
Vutr Boles; 1988; 27(6):55-8. PubMed ID: 3247706
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of Raynaud's syndrome with calcium entry blockers].
Shcherbakov AB; Guseva NG; Mach ES
Ter Arkh; 1987; 59(4):89-92. PubMed ID: 3296288
[TBL] [Abstract][Full Text] [Related]
3. [Calcium antagonists and Raynaud's phenomenon].
Hachulla E; Devulder B
Therapie; 1993; 48 Spec No():707-11. PubMed ID: 8091357
[TBL] [Abstract][Full Text] [Related]
4. Nifedipine and Raynaud's phenomenon associated with connective tissue diseases.
Kahan A; Weber S; Amor B; Menkes CJ; Hodara M; Degeorges M
Int Angiol; 1985; 4(2):221-3. PubMed ID: 3831143
[TBL] [Abstract][Full Text] [Related]
5. [Calcium antagonists for the treatment of Raynaud's phenomenon].
Müller-Bühl U; Diehm C; Scheuermann W; Mörl H
Dtsch Med Wochenschr; 1983 Nov; 108(47):1795-7. PubMed ID: 6357692
[TBL] [Abstract][Full Text] [Related]
6. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
[TBL] [Abstract][Full Text] [Related]
7. [Controlled study of nifedipine in the treatment of Raynaud's phenomenon].
Kahan A; Weber S; Amor B; Saporta L; Hodara M; Degeorges M
Rev Rhum Mal Osteoartic; 1982 Apr; 49(5):337-43. PubMed ID: 6285445
[TBL] [Abstract][Full Text] [Related]
8. Vascular response of Raynaud's phenomenon to nifedipine or herbal medication (duhuo-tisheng tang with danggui-sini tang): a preliminary study.
Wu YJ; Luo SF; Yang SH; Chen JY; Yu KH; See LC
Chang Gung Med J; 2008; 31(5):492-502. PubMed ID: 19097597
[TBL] [Abstract][Full Text] [Related]
9. The peripheral vascular effects of nifedipine in Raynaud's syndrome associated with scleroderma: a double blind crossover study.
Finch MB; Dawson J; Johnston GD
Clin Rheumatol; 1986 Dec; 5(4):493-8. PubMed ID: 3816096
[TBL] [Abstract][Full Text] [Related]
10. Nifedipine in Raynaud's phenomenon: relationship between immediate, short term and longterm effects.
Kallenberg CG; Wouda AA; Kuitert JJ; Tijssen J; Wesseling H
J Rheumatol; 1987 Apr; 14(2):284-90. PubMed ID: 3598997
[TBL] [Abstract][Full Text] [Related]
11. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
[TBL] [Abstract][Full Text] [Related]
12. Nifedipine in the treatment of idiopathic Raynaud's syndrome.
Sarkozi J; Bookman AA; Mahon W; Ramsay C; Detsky AS; Keystone EC
J Rheumatol; 1986 Apr; 13(2):331-6. PubMed ID: 3723496
[TBL] [Abstract][Full Text] [Related]
13. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
Fries R; Shariat K; von Wilmowsky H; Böhm M
Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
[TBL] [Abstract][Full Text] [Related]
14. Raynaud's phenomenon: pathophysiologic features and treatment with calcium-channel blockers.
Smith CR; Rodeheffer RJ
Am J Cardiol; 1985 Jan; 55(3):154B-157B. PubMed ID: 3881908
[TBL] [Abstract][Full Text] [Related]
15. [The therapy of Raynaud's phenomenon].
Di Giacinto G
Clin Ter; 1993 Feb; 142(2):161-74. PubMed ID: 8472530
[TBL] [Abstract][Full Text] [Related]
16. [Corinfar in the treatment of Raynaud's syndrome in systemic scleroderma (preliminary results)].
Shcherbakov AB; Guseva NG; Mach ES
Ter Arkh; 1985; 57(5):141-4. PubMed ID: 4023933
[TBL] [Abstract][Full Text] [Related]
17. [Diagnosis and treatment of Raynaud's phenomenon].
Guilmot JL; Diot E; Lasfargues G
Arch Mal Coeur Vaiss; 1991 Nov; 84(11 Suppl):1755-60. PubMed ID: 1685081
[TBL] [Abstract][Full Text] [Related]
18. [Action of nifedipine on the post-ischemic cold hyperemia reaction in Raynaud's phenomenon].
Vayssairat M; Blaison N; Baudot N; Evenou P; Gilard M; Mathieu JF
J Mal Vasc; 1989; 14(4):299-302. PubMed ID: 2584886
[TBL] [Abstract][Full Text] [Related]
19. The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases.
Rychlik-Golema W; Mastej K; Adamiec R
Int Angiol; 2006 Jun; 25(2):221-7. PubMed ID: 16763543
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Raynaud's phenomenon with calcium channel blockers.
Smith CR; Rodeheffer RJ
Am J Med; 1985 Feb; 78(2B):39-42. PubMed ID: 3976694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
